Drug Discovery@nature.com 2 August 2013

Advertisement Just one of many high quality articles Frontiers in Pharmacology has to offer:  Mechanisms and insights into drug resistance in cancer (open access) In this Review, Hiba Zahreddine and Katherine Borden discuss different mechanisms adapted by cancerous cells to resist treatment, including alteration in drug transport and metabolism, mutation and amplification of drug targets, as well as genetic rewiring which can lead to impaired apoptosis. TABLE OF CONTENTS 2 August 2013 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement SciBX is pleased to present: SciBX Summit on Innovation in Drug Discovery and Development 2013 October 29-30, 2013 The Colonnade Hotel, Boston, MA, USA  Click here for more information or to register for this conference today!   News Top Revolution dawning in cardiotoxicity testing doi:10.1038/nrd4083 Stem cell technology and computational modelling offer the promise of reducing the current burden of cardiotoxicity assessment. Full Text Trial watch: Phase II and Phase III attrition rates 2011-2012 doi:10.1038/nrd4090 The authors conduct an analysis of the rates and causes of drug candidate attrition by clinical development phase and by therapeutic area for 2011 and 2012. Full Text Patent watch: Isolated DNA patent ban creates muddy waters for biomarkers and natural products doi:10.1038/nrd4084 The full implications of the recent ruling by the US Supreme Court that isolated DNA is not eligible for patenting are unclear. Full Text An audience with: Lee M. Ellis doi:10.1038/nrd4085 The lead author of the ASCO's draft guidelines to “raise the bar” for cancer clinical trials discusses the aims and potential impact of the guidelines on anticancer drug development. Full Text Analysis Top MPS IIIA: gene therapy for brain and body doi:10.1038/scibx.2013.709 Within a year of reporting preclinical proof of concept for a systemically delivered MPS IIIA gene therapy, researchers have substantially improved efficacy in the CNS while still treating peripheral organs via intracerebral delivery. Full Text Novelty in the target landscape of the pharmaceutical industry doi:10.1038/nrd4089 An analysis of the overlap in the drug targets that are being pursued across the industry indicates that more than half of the novel drug targets in current pipelines are being pursued by only one company. Full Text Research Highlights Top Mood disorders: Room for improvement doi:10.1038/nrd4078 Two independent studies shed light on the mechanism of action of commonly prescribed antidepressants and suggest new therapeutic targets. Full Text G protein-coupled receptors: Two landmark class B GPCR structures unveiled doi:10.1038/nrd4082 High-resolution crystal structures of the human corticotropin-releasing factor 1 (CRF1) receptor and the human glucagon receptor are reported in Nature. Full Text Influenza: Viral vector delivers protective antibodies doi:10.1038/nrd4079 Vectored immunoprophylaxis durably protects even immunocompromised mice from illness caused by diverse influenza strains. Full Text Research & Reviews Top Validating therapeutic targets through human genetics doi:10.1038/nrd4051 Many clinical trial failures can be traced back to the limited predictive value of preclinical models of disease. This Review discusses how knowledge from human genetics can be used as a tool to more effectively prioritize molecular targets in drug development. Full Text Gene-engineered T cells for cancer therapy doi:10.1038/nrc3565 Adoptive T cell therapy using engineered T cells to improve antitumour responses is showing promise for the treatment of haematological malignancies in particular. This Review discusses the strategies and progress being made to engineer T cells to treat cancer patients. Full Text Bringing genome-wide association findings into clinical use doi:10.1038/nrg3523 Despite the impact of genome-wide association studies (GWASs) on disease genetics, there has been scepticism about their usefulness in clinical translation. This Review highlights pertinent examples in which clinical application has been achieved and considers the wider potential for translation. Full Text Applications of nanotechnology for immunology doi:10.1038/nri3488 This Review describes how the unique properties of different nanostructures can be used to either enhance or to suppress immune responses, and discusses the promise of these strategies for developing more effective immunotherapies. Full Text Drug Discovery JOBS of the week Research Associate II Oncology Drug Discovery, Biology Johnson & Johnson Investigator, Computer-Aided Drug Design China Novartis Institutes for BioMedical Research Co., Ltd. (CNIBR) PhD project on lncRNA role in cancer drug activity University of Rennes 1 Postdoctoral positions in GPCR Drug Discovery UNC Chapel Hill School of Medicine PhD in Biomedical Engineering: Ultrasound for Drug Delivery University of Glasgow More Science jobs from Drug Discovery EVENT Resources for Computational Drug Discovery 09.12.13 Cambridge, UK More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.